Immunome Financial Statements (IMNM)
|
|
|
|
Report date
|
|
|
19.03.2025 |
12.05.2025 |
06.08.2025 |
06.11.2025 |
03.03.2026 |
|
03.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2.74 |
2.93 |
4.02 |
0.000 |
0.000 |
|
6.94 |
|
Operating Income, bln rub |
|
|
-83.0 |
-44.6 |
-46.5 |
-60.1 |
-62.9 |
|
-214.1 |
|
EBITDA, bln rub |
? |
|
-55.0 |
-43.9 |
-45.8 |
-56.9 |
-62.1 |
|
-208.6 |
|
Net profit, bln rub |
? |
|
-80.2 |
-41.6 |
-43.4 |
-57.5 |
-69.9 |
|
-212.4 |
|
|
OCF, bln rub |
? |
|
-42.1 |
-53.1 |
-49.4 |
-40.5 |
-48.0 |
|
-190.9 |
|
CAPEX, bln rub |
? |
|
1.38 |
3.67 |
0.905 |
1.12 |
4.00 |
|
9.69 |
|
FCF, bln rub |
? |
|
-43.4 |
-56.7 |
-50.3 |
-41.6 |
-52.0 |
|
-200.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
85.7 |
47.6 |
49.8 |
10.9 |
62.1 |
|
170.4 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.720 |
49.2 |
0.776 |
|
50.7 |
|
R&D, bln rub |
|
|
47.9 |
36.9 |
40.5 |
49.2 |
50.8 |
|
177.3 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
240.2 |
342.7 |
296.3 |
299.4 |
683.2 |
|
683.2 |
|
Net Assets, bln rub |
? |
|
181.2 |
307.1 |
269.3 |
263.9 |
634.3 |
|
634.3 |
|
Debt, bln rub |
|
|
4.83 |
4.77 |
4.14 |
4.01 |
3.86 |
|
3.86 |
|
Cash, bln rub |
|
|
217.3 |
317.3 |
268.0 |
272.6 |
653.5 |
|
653.5 |
|
Net debt, bln rub |
|
|
-212.5 |
-312.6 |
-263.9 |
-268.6 |
-649.6 |
|
-649.6 |
|
|
Ordinary share price, rub |
|
|
10.6 |
6.73 |
9.30 |
11.7 |
21.5 |
|
22.7 |
|
Number of ordinary shares, mln |
|
|
62.7 |
79.4 |
87.0 |
88.0 |
87.4 |
|
87.4 |
|
|
Market cap, bln rub |
|
|
666 |
534 |
809 |
1 030 |
1 876 |
|
1 980 |
|
EV, bln rub |
? |
|
453 |
222 |
545 |
761 |
1 227 |
|
1 331 |
|
Book value, bln rub |
|
|
181 |
307 |
269 |
264 |
634 |
|
634 |
|
|
EPS, rub |
? |
|
-1.28 |
-0.52 |
-0.50 |
-0.65 |
-0.80 |
|
-2.43 |
|
FCF/share, rub |
|
|
-0.69 |
-0.71 |
-0.58 |
-0.47 |
-0.59 |
|
-2.30 |
|
BV/share, rub |
|
|
2.89 |
3.87 |
3.09 |
3.00 |
7.26 |
|
7.26 |
|
|
EBITDA margin, % |
? |
|
-2 009% |
-1 501% |
-1 140% |
|
|
|
-3 006% |
|
Net margin, % |
? |
|
-2 931% |
-1 423% |
-1 081% |
|
|
|
-3 060% |
|
FCF yield, % |
? |
|
-17.8% |
-30.2% |
-23.0% |
-18.6% |
-10.7% |
|
-10.1% |
|
ROE, % |
? |
|
-161.7% |
-66.8% |
-78.9% |
-84.4% |
-33.5% |
|
-33.5% |
|
ROA, % |
? |
|
-121.9% |
-59.9% |
-71.7% |
-74.4% |
-31.1% |
|
-31.1% |
|
|
P/E |
? |
|
-2.27 |
-2.61 |
-3.81 |
-4.62 |
-8.83 |
|
-9.32 |
|
P/FCF |
|
|
-5.63 |
-3.31 |
-4.35 |
-5.36 |
-9.35 |
|
-9.87 |
|
P/S |
? |
|
73.7 |
48.9 |
64.3 |
106.4 |
270.3 |
|
285.3 |
|
P/BV |
? |
|
3.68 |
1.74 |
3.01 |
3.90 |
2.96 |
|
3.12 |
|
EV/EBITDA |
? |
|
-3.00 |
-1.27 |
-2.90 |
-3.78 |
-5.88 |
|
-6.38 |
|
Debt/EBITDA |
|
|
1.40 |
1.78 |
1.40 |
1.33 |
3.11 |
|
3.11 |
|
|
R&D/CAPEX, % |
|
|
3 483% |
1 006% |
4 470% |
4 408% |
1 270% |
|
1 831% |
|
|
CAPEX/Revenue, % |
|
|
50.2% |
125.3% |
22.5% |
|
|
|
139.5% |
|
| Immunome shareholders |
